Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DLMAF

Go back to Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

Xencor (XNCR) Misses Q3 EPS by 4c

November 8, 2021 4:21 PM EST

Xencor (NASDAQ: XNCR) reported Q3 EPS of ($0.69), $0.04 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $19.04 million.

For earnings history and earnings-related data on Xencor (XNCR) click here.

... More